{"prompt": "['Trial ID: LP0162-1325', 'Date: 14-Aug-2018', 'Version: 4.0', 'Page 159 of 169', 'Section number', 'Description of change', 'Brief rationale', 'and name', 'Section 12.3.6.2.3', 'To support the maintenance objective, the', 'To clarify that only', 'response IGA 0/1 or EASI75 at Week 52 will', 'Supportive', 'subjects who achieve', 'maintenance', 'be presented and analysed as described above', 'response at Week 16', 'for the primary analysis of the maintenance', 'without rescue medication', 'estimand for all-subjects in the maintenance', 'will be included in the', 'analysis set who did not receive rescue', 'analysis.', 'medication prior to Week 16 The estimated', 'response rates and corresponding 95% CIs, and', 'the pairwise treatment differences will be', 'presented.', 'Section 12.3.9', 'This is a new section which specifies that the', 'To support submission for', 'Analysis of data per', 'trial will be unblinded once all randomised', 'regulatory approval.', \"last subject's\", 'subjects have completed the Week 52 visit. All', 'Week 52 visit', 'pre-specified analyses related to the initial and', 'maintenance treatment period will be based on', \"the data cut-off date of the last subject's\", 'Week 52 visit.', 'Appendix 1', 'Updated with the changes described above, as', 'To reflect updated text in', 'Protocol summary', 'applicable.', 'protocol.', 'Appendix 4B', 'Subjects must be re-consented to the most', 'Clarification that subjects', 'Informed consent', 'current version of the ICF(s) during their', 'will only be re-consented', 'participation in the trial, if required.', 'to a new version of the', 'process', 'ICF(s), if deemed', 'necessary.', 'Appendix 4H', 'Refer to Appendix 8 for contact details', 'a', 'As the DMC has been', 'Committee structure', 'list of trial committee members.', 'established, the list of', 'committee members has', 'been included; however,', 'contact details are not', 'provided in the protocol.', 'Appendix 8', 'Members of the DMC have been listed.', 'DMC has now been', 'Contact list', 'contracted.', 'Throughout', 'Minor editorial and document formatting', 'Minor, have therefore not', 'revisions.', 'been summarised.', 'eDoc-00631888 - Version 4.0']['Trial ID: LP0162-1325', 'Date: 14-Aug-2018', 'Version: 4.0', 'Page 160 of 169', 'Amendment 1 (28-Aug-2017)', 'This amendment is considered to be substantial based on the criteria set forth in Article 10(a)', 'of Directive 2001/20/EC of the European Parliament and the Council of the European Union.', 'Overall rationale for the amendment', 'The reason for the amendment is due to a request for changes from the Health Authorities in', 'Europe after their review of the protocol.', 'Note: In the table below, text added to the protocol is written in bold and deleted text has', 'a', 'line through it.', 'Section number and', 'Description of change', 'Brief rationale', 'name', 'Section 2', 'ClinicalTrials.gov number:', 'ClinicalTrials.gov identifier', 'Trial identification', 'NCT03131648', 'received and it has therefore been', 'added.', 'Section 3', 'All subjects in the trial will have a', 'To ensure that safety follow-up', 'safety follow-up visit (end of trial', 'information is collected for all', 'Schematic of trial', 'design', 'visit) 16 weeks after last injection of', 'subjects enrolled in this trial, and', 'IMP, including those that are offered', 'to ensure that a safety evaluation', 'Section 4', 'participation in the long-term', 'can be made based on data', 'Schedule of', 'extension trial conducted under a', 'collected after IMP has been', 'procedures', 'separate protocol (LP0162-1337).', 'discontinued. Furthermore, the', 'Section 7.1', 'evaluation of anti-drug antibodies', 'is considered to be most reliable', 'Overall trial design', 'when samples are taken in the', 'Section 7.3', 'absence of IMP.', 'End of trial definition', 'Details regarding enrolment of', 'Details regarding enrolment of', 'subjects into the long-term extension', 'subjects into trial LP0162-1337', 'have been removed.', 'will be described in the protocol', 'for LP0162-1337.', 'Section 4', '2 blood samples (PK and anti-drug', 'To better monitor potential', 'Schedule of', 'antibodies) have been added at', 'development of immunogenicity.', 'procedures', 'Week 4 (visit 5).', 'eDoc-00631888 - Version 4.0']\n\n###\n\n", "completion": "END"}